Special Issue "Role and Significance of Vaccines Against Animal Brucellosis"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 November 2023 | Viewed by 2644
Brucellosis remains a formidable challenge, recognized by the WHO as one of the most significant occupational and public health zoonoses, globally, and is still endemic in large parts of the world. Historically, Brucella melitensis, B. abortus, and B. suis were first identified as human zoonotic agents, instigating research programs on their pathogenesis and taxonomic structure which associated them with natural host animals in which they cause abortion storms at the third trimester. The growing evidence regarding their zoonotic potential and association of these bacteria with domesticated animals led to developing the serological and bacteriological standards necessary to act as regulatory tools in activating national and international animal trading policies. Simultaneously, live attenuated strains were developed as superior animal vaccines in comparison to sub-unit and killed vaccines. However, these vaccines caused problems linked to differentiating infected from vaccinated animals (DIVA) as well as being zoonotic to users., which biased control programs. In recent years, scientists have focused on the identification and characterization of novel Brucella species and their phylogenetic backgrounds, shedding light on the diversion between “classical Brucella” and earlier precursor lineages during the evolution of the genus. To this end, new high-throughput molecular approaches have been added as scientific tools in the combat against the disease.
We are enthusiastic to open this Special Issue on brucellosis and other zoonotic diseases, with the aim of widening our knowledge on this important disease.
We thus invite submission of research and review articles in the field of brucellosis which could enlighten us on the following subjects: identification and characterization of novel Brucella strains, molecular and bacteriological typing approaches, diagnosis, epidemiology, laboratory works with clinical samples, and research and development of novel vaccines.
Dr. Menachem Banai
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.